168 related articles for article (PubMed ID: 34673585)
1. HER2 testing by immunohistochemistry in breast cancer: A multicenter proficiency ring study.
Md Pauzi SH; Masir N; Yahaya A; Mohammed F; Tizen Laim NMS; Mustangin M; Aizudin AN; Talib A; Teoh KH; Karim N; Oy-Leng JW; Rajadurai P
Indian J Pathol Microbiol; 2021; 64(4):677-682. PubMed ID: 34673585
[TBL] [Abstract][Full Text] [Related]
2. "HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH" Answer to the statistical issue to avoid misinterpretation.
Casterá Redal C; Bernet Vegué L
Ann Diagn Pathol; 2020 Oct; 48():151566. PubMed ID: 32763505
[TBL] [Abstract][Full Text] [Related]
3. HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH.
Casterá C; Bernet L
Ann Diagn Pathol; 2020 Apr; 45():151451. PubMed ID: 31955049
[TBL] [Abstract][Full Text] [Related]
4. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study.
Vincent-Salomon A; MacGrogan G; Couturier J; Arnould L; Denoux Y; Fiche M; Jacquemier J; Mathieu MC; Penault-Llorca F; Rigaud C; Roger P; Treilleux I; Vilain MO; Mathoulin-Pélissier S; Le Doussal V
Histopathology; 2003 Apr; 42(4):337-47. PubMed ID: 12653945
[TBL] [Abstract][Full Text] [Related]
5. Standardization of HER2 testing: results of an international proficiency-testing ring study.
Dowsett M; Hanna WM; Kockx M; Penault-Llorca F; Rüschoff J; Gutjahr T; Habben K; van de Vijver MJ
Mod Pathol; 2007 May; 20(5):584-91. PubMed ID: 17396141
[TBL] [Abstract][Full Text] [Related]
6. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Wolff AC; Hammond ME; Schwartz JN; Hagerty KL; Allred DC; Cote RJ; Dowsett M; Fitzgibbons PL; Hanna WM; Langer A; McShane LM; Paik S; Pegram MD; Perez EA; Press MF; Rhodes A; Sturgeon C; Taube SE; Tubbs R; Vance GH; van de Vijver M; Wheeler TM; Hayes DF; ;
J Clin Oncol; 2007 Jan; 25(1):118-45. PubMed ID: 17159189
[TBL] [Abstract][Full Text] [Related]
7. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.
van de Vijver M; Bilous M; Hanna W; Hofmann M; Kristel P; Penault-Llorca F; Rüschoff J
Breast Cancer Res; 2007; 9(5):R68. PubMed ID: 17922920
[TBL] [Abstract][Full Text] [Related]
8. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
Yardley DA; Kaufman PA; Huang W; Krekow L; Savin M; Lawler WE; Zrada S; Starr A; Einhorn H; Schwartzberg LS; Adams JW; Lie Y; Paquet AC; Sperinde J; Haddad M; Anderson S; Brigino M; Pesano R; Bates MP; Weidler J; Bosserman L
Breast Cancer Res; 2015 Mar; 17(1):41. PubMed ID: 25886996
[TBL] [Abstract][Full Text] [Related]
9. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays.
Laurinaviciene A; Dasevicius D; Ostapenko V; Jarmalaite S; Lazutka J; Laurinavicius A
Diagn Pathol; 2011 Sep; 6():87. PubMed ID: 21943197
[TBL] [Abstract][Full Text] [Related]
10. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Wolff AC; Hammond ME; Schwartz JN; Hagerty KL; Allred DC; Cote RJ; Dowsett M; Fitzgibbons PL; Hanna WM; Langer A; McShane LM; Paik S; Pegram MD; Perez EA; Press MF; Rhodes A; Sturgeon C; Taube SE; Tubbs R; Vance GH; van de Vijver M; Wheeler TM; Hayes DF;
Arch Pathol Lab Med; 2007; 131(1):18-43. PubMed ID: 19548375
[TBL] [Abstract][Full Text] [Related]
11. Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.
Solomon JP; Dell'Aquila M; Fadare O; Hasteh F
Am J Clin Pathol; 2017 Apr; 147(4):432-437. PubMed ID: 28340220
[TBL] [Abstract][Full Text] [Related]
12. Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey.
Fitzgibbons PL; Murphy DA; Dorfman DM; Roche PC; Tubbs RR;
Arch Pathol Lab Med; 2006 Oct; 130(10):1440-5. PubMed ID: 17090184
[TBL] [Abstract][Full Text] [Related]
13. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
14. HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation.
Sheffield BS; Garratt J; Kalloger SE; Li-Chang HH; Torlakovic EE; Gilks CB; Schaeffer DF
Arch Pathol Lab Med; 2014 Nov; 138(11):1495-502. PubMed ID: 25357111
[TBL] [Abstract][Full Text] [Related]
15. Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program.
Bilous M; Morey AL; Armes JE; Bell R; Button PH; Cummings MC; Fox SB; Francis GD; Waite B; McCue G; Raymond WA; Robbins PD; Farshid G
Breast Cancer Res Treat; 2012 Jul; 134(2):617-24. PubMed ID: 22678156
[TBL] [Abstract][Full Text] [Related]
16. HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry.
Kovács A; Stenman G
Pathol Res Pract; 2010 Jan; 206(1):39-42. PubMed ID: 19819642
[TBL] [Abstract][Full Text] [Related]
17. Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection.
Prendeville S; Feeley L; Bennett MW; O'Connell F; Browne TJ
Am J Clin Pathol; 2016 Jan; 145(1):75-80. PubMed ID: 26712873
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISH.
Jensen SG; Thomas PE; Christensen IJ; Balslev E; Hansen A; Høgdall E
APMIS; 2020 Nov; 128(11):573-582. PubMed ID: 32860265
[TBL] [Abstract][Full Text] [Related]
19. An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.
Wesseling J; Tinterri C; Sapino A; Zanconati F; Lutke-Holzik M; Nguyen B; Deck KB; Querzoli P; Perin T; Giardina C; Seitz G; Guinebretière JM; Barone J; Dekker L; de Snoo F; Stork-Sloots L; Roepman P; Watanabe T; Cusumano P
Virchows Arch; 2016 Sep; 469(3):297-304. PubMed ID: 27377889
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).
Perez EA; Press MF; Dueck AC; Jenkins RB; Kim C; Chen B; Villalobos I; Paik S; Buyse M; Wiktor AE; Meyer R; Finnigan M; Zujewski J; Shing M; Stern HM; Lingle WL; Reinholz MM; Slamon DJ
Breast Cancer Res Treat; 2013 Feb; 138(1):99-108. PubMed ID: 23420271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
